## Ilan Goldenberg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5175023/publications.pdf Version: 2024-02-01



LIAN COLDENBERC

#	Article	IF	CITATIONS
1	Use of oral contraceptives in women with congenital long QT syndrome. Heart Rhythm, 2022, 19, 41-48.	0.7	7
2	Arrhythmic and Mortality Outcomes Among Ischemic Versus Nonischemic Cardiomyopathy Patients Receiving Primary ICD Therapy. JACC: Clinical Electrophysiology, 2022, 8, 1-11.	3.2	12
3	Radial strain imaging-guided lead placement for improving response to cardiac resynchronization therapy in patients with ischaemic cardiomyopathy: the Raise CRT trial. Europace, 2022, 24, 835-844.	1.7	9
4	Machine learning-based prediction of 1-year mortality for acute coronary syndrome✰. Journal of Cardiology, 2022, 79, 342-351.	1.9	8
5	Junctional AV ablation in patients with atrial fibrillation undergoing cardiac resynchronization therapy (JAVA-CRT): results of a multicenter randomized clinical trial pilot program. Journal of Interventional Cardiac Electrophysiology, 2022, 64, 519-530.	1.3	1
6	Outcomes Associated with Introduction of the 5th Generation High-Sensitivity Cardiac Troponin in Patients Presenting with Cardiovascular Disorders. Journal of Emergency Medicine, 2022, , .	0.7	2
7	Reduction in Ventricular Tachyarrhythmia Burden in Patients Enrolled in the RAIDÂTrial. JACC: Clinical Electrophysiology, 2022, , .	3.2	Ο
8	Sex hormones and repolarization dynamics during the menstrual cycle in women with congenital long QT syndrome. Heart Rhythm, 2022, 19, 1532-1540.	0.7	6
9	Intraoperative Ventricular Tachycardia Ablation During Left Ventricular Assist Device Implantation in High-Risk Heart Failure Patients. Circulation: Arrhythmia and Electrophysiology, 2022, 15, .	4.8	4
10	Sex Differences in the Risk of First and Recurrent Ventricular Tachyarrhythmias Among Patients Receiving an Implantable Cardioverter-Defibrillator for Primary Prevention. JAMA Network Open, 2022, 5, e2217153.	5.9	6
11	Role of Implantable Cardioverter Defibrillator in Heart Failure With Contemporary Medical Therapy. Circulation: Heart Failure, 2022, 15, .	3.9	6
12	Risk of arrhythmic events after alcohol septal ablation for hypertrophic cardiomyopathy using continuous implantable cardiac monitoring. Heart Rhythm, 2021, 18, 50-56.	0.7	7
13	Telehealth for the Management of Left Ventricular Assist Device Patients: The University of Rochester TeleLVAD Study. Journal of Cardiac Failure, 2021, 27, 112-113.	1.7	3
14	Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score. European Heart Journal, 2021, 42, 1676-1684.	2.2	61
15	Outcome of patients with prior coronary bypass surgery admitted with an acute coronary syndrome. Heart, 2021, 107, heartjnl-2020-318047.	2.9	1
16	Systolic Blood Pressure and Risk for Ventricular Arrhythmia in Patients With an Implantable Cardioverter Defibrillator. American Journal of Cardiology, 2021, 143, 74-79.	1.6	3
17	Risk factors for ventricular tachyarrhythmic events in patients without left bundle branch block who receive cardiac resynchronization therapy. Annals of Noninvasive Electrocardiology, 2021, 26, e12847.	1.1	1
18	Extending the MADIT-ICD benefit score to heterogenous heart failure populations. European Heart Journal, 2021, 42, 4774-4775.	2.2	2

#	Article	IF	CITATIONS
19	Cardiac resynchronization therapy and ventricular tachyarrhythmia burden. Heart Rhythm, 2021, 18, 762-769.	0.7	14
20	Ethnic Disparity in Mortality Among Ischemic Heart Disease Patients. A-20 Years Outcome Study From Israel. Frontiers in Cardiovascular Medicine, 2021, 8, 661390.	2.4	2
21	Risk Prediction in Women With Congenital Long QT Syndrome. Journal of the American Heart Association, 2021, 10, e021088.	3.7	7
22	Temporal trends in prognosis of patients with acute coronary syndrome complicated by ventricular tachyarrhythmia. International Journal of Clinical Practice, 2021, 75, e14623.	1.7	0
23	Combining diastolic dysfunction and natriuretic peptides to risk stratify patients with heart failure with reduced ejection fraction. International Journal of Cardiology, 2021, 335, 59-65.	1.7	2
24	Comparison of Low and Full Dose Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Renal Dysfunction (from a National Registry). American Journal of Cardiology, 2021, 159, 87-93.	1.6	1
25	Hospitalization for HeartÂFailure and Subsequent Ventricular Tachyarrhythmias in Patients With LeftÂVentricular Dysfunction. JACC: Clinical Electrophysiology, 2021, 7, 1099-1107.	3.2	0
26	Predicting 30-day mortality after ST elevation myocardial infarction: Machine learning- based random forest and its external validation using two independent nationwide datasets. Journal of Cardiology, 2021, 78, 439-446.	1.9	16
27	Heart Team/Guidelines Discordance Is Associated With Increased Mortality: Data From a National Survey of Revascularization in Patients With Complex Coronary Artery Disease. Circulation: Cardiovascular Interventions, 2021, 14, e009686.	3.9	6
28	Safety of High-Dose Dabigatran in Elderly and Younger Patients with a Low Bleeding Risk: A Prospective Observational Study. Cardiology, 2021, 146, 641-645.	1.4	1
29	Sex-Specific Platelet Activation Through Protease-Activated Receptors Reverses in Myocardial Infarction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 390-400.	2.4	11
30	Effectiveness of Implantable Cardioverter-Defibrillators to ReduceÂMortality in Patients With LongÂQT Syndrome. Journal of the American College of Cardiology, 2021, 78, 2076-2088.	2.8	14
31	Apixaban in Patients with Atrial Fibrillation and Severe Renal Dysfunction: Findings from a National Registry. Israel Medical Association Journal, 2021, 23, 353-358.	0.1	1
32	Do all intra-ventricular conduction defect ECG patterns respond equally to CRT?. Journal of Interventional Cardiac Electrophysiology, 2020, 58, 87-94.	1.3	4
33	The role of implantable cardioverter-defibrillators and sudden cardiac death prevention: indications, device selection, and outcome. European Heart Journal, 2020, 41, 2003-2011.	2.2	22
34	Prognostic Usefulness of Systolic Blood Pressure One-Year Following Cardiac Resynchronization Therapy (from MADIT-CRT). American Journal of Cardiology, 2020, 125, 777-782.	1.6	1
35	Avoidance of Coronary Angiography in High-Risk Patients With Acute Coronary Syndromes: The ACSIS Registry Findings. Cardiovascular Revascularization Medicine, 2020, 21, 1230-1236.	0.8	6
36	Implantation of a fully magnetically levitated left ventricular assist device using a sternal-sparing surgical technique. Journal of Heart and Lung Transplantation, 2020, 39, 37-44.	0.6	36

#	Article	IF	CITATIONS
37	Predictors and outcomes of atrial tachyarrhythmia among patients with implantable defibrillators. Heart Rhythm, 2020, 17, 553-559.	0.7	5
38	Outcome by Sex in Patients With Long QT Syndrome With an Implantable Cardioverter Defibrillator. Journal of the American Heart Association, 2020, 9, e016398.	3.7	4
39	Utility of 6-Minute Walk Test to Predict Response to Cardiac Resynchronization Therapy in Patients With Mild Heart Failure. American Journal of Cardiology, 2020, 132, 79-86.	1.6	1
40	Ethnic Differences Among Acute Coronary Syndrome Patients in Israel. Cardiovascular Revascularization Medicine, 2020, 21, 1431-1435.	0.8	6
41	Association of previous cardiac surgery with outcomes in left ventricular assist device patients. Interactive Cardiovascular and Thoracic Surgery, 2020, 31, 1-8.	1.1	4
42	High fitness might be associated with the development of newâ€onset atrial fibrillation in obese nonâ€athletic adults. International Journal of Clinical Practice, 2020, 74, e13638.	1.7	1
43	Long-term milrinone therapy as a bridge to heart transplantation: Safety, efficacy, and predictors of failure. International Journal of Cardiology, 2020, 313, 83-88.	1.7	11
44	Norton score and clinical outcomes following acute decompensated heart failure hospitalization. Journal of Cardiology, 2020, 76, 335-341.	1.9	9
45	The role and outcomes of new supraventricular tachycardia among patients with mild heart failure. Journal of Cardiovascular Electrophysiology, 2020, 31, 1099-1104.	1.7	Ο
46	Cardiac Resynchronization Therapy and Risk of Recurrent Hospitalizations in Patients Without Left Bundle Branch Block. Circulation: Heart Failure, 2020, 13, e006925.	3.9	3
47	Circadian variation and seasonal distribution of implantable defibrillator detected new onset atrial fibrillation. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 1495-1500.	1.2	4
48	Implantable cardioverter-defibrillator programming after first occurrence of ventricular tachycardia in the Multicenter Automatic Defibrillator Implantation Trial–Reduce Inappropriate Therapy (MADIT-RIT). Heart Rhythm O2, 2020, 1, 77-82.	1.7	4
49	Patient selection for wearable cardioverter defibrillator therapy after myocardial infarction: How can we incorporate compliance into decisionâ€making?. Journal of Cardiovascular Electrophysiology, 2020, 31, 1019-1021.	1.7	3
50	Relation between resting heart rate and the risk of ventricular tachyarrhythmias in MADIT-RIT. Europace, 2020, 22, 281-287.	1.7	3
51	Need for pacing in patients who qualify for an implantable cardioverterâ€defibrillator: Clinical implications for the subcutaneous ICD. Annals of Noninvasive Electrocardiology, 2020, 25, e12744.	1.1	8
52	The role of implantable cardioverter-defibrillators in asymptomatic patients with left ventricular dysfunction. European Heart Journal, 2020, 41, 2035-2035.	2.2	1
53	Trends in long-term prognosis according to left ventricular ejection fraction after acute coronary syndrome. Journal of Cardiology, 2020, 76, 303-308.	1.9	10
54	Genotype-Phenotype Correlation in Congenital LQTS: Implications for Diagnosis and Risk		1

Stratification. , 2020, , 141-164.

#	Article	IF	CITATIONS
55	Response to "How to consider optimal therapeutic strategy for bridge to heart transplantationâ€. International Journal of Cardiology, 2020, 320, 126.	1.7	0
56	Arrhythmia Burden in Patients with Indolent Lymphoma. Blood, 2020, 136, 6-7.	1.4	1
57	Primary prevention with the implantable cardioverter-defibrillator in high-risk long-QT syndrome patients. Europace, 2019, 21, 339-346.	1.7	22
58	Association of Bezafibrate Treatment With Reduced Risk of Cancer in Patients With Coronary Artery Disease. Mayo Clinic Proceedings, 2019, 94, 1171-1179.	3.0	4
59	Death with an implantable cardioverter-defibrillator: a MADIT-II substudy. Europace, 2019, 21, 1843-1850.	1.7	5
60	Thrombocytopenia and thrombocytosis are associated with different outcome in atrial fibrillation patients on anticoagulant therapy. PLoS ONE, 2019, 14, e0224709.	2.5	4
61	Association of Cardiac Resynchronization Therapy With Change in Left Ventricular Ejection Fraction in Patients With Chemotherapy-Induced Cardiomyopathy. JAMA - Journal of the American Medical Association, 2019, 322, 1799.	7.4	32
62	QRS change in heart failure: When is the right time for cardiac resynchronization therapy?. International Journal of Cardiology, 2019, 296, 87-88.	1.7	0
63	Left Ventricular Reverse Remodeling in Cardiac Resynchronization Therapy and Long-TermÂOutcomes. JACC: Clinical Electrophysiology, 2019, 5, 1001-1010.	3.2	16
64	Risk of Ventricular Tachyarrhythmic Events in Patients Who Improved BeyondÂGuidelines for a Defibrillator inÂMADIT-CRT. JACC: Clinical Electrophysiology, 2019, 5, 1172-1181.	3.2	3
65	Comparison of Outcomes in Patients With Acute Coronary Syndrome Presenting With Typical Versus Atypical Symptoms. American Journal of Cardiology, 2019, 124, 1851-1856.	1.6	10
66	Sildenafil for Pulmonary Hypertension in the Early Postoperative Period After Mitral Valve Surgery. Journal of Cardiothoracic and Vascular Anesthesia, 2019, 33, 1648-1656.	1.3	11
67	Trends in management and outcome of acute coronary syndrome in women ≥80†years versus those <80†years in Israel from 2000–2016. International Journal of Cardiology, 2019, 281, 22-27.	1.7	2
68	Arrhythmic burden among asymptomatic patients with ischemic cardiomyopathy and an implantable cardioverter-defibrillator. Heart Rhythm, 2019, 16, 813-819.	0.7	5
69	Statin therapy among chronic kidney disease patients presenting with acute coronary syndrome. Atherosclerosis, 2019, 286, 14-19.	0.8	7
70	Prognostic Importance of Defibrillatorâ€Appropriate Shocks and Antitachycardia Pacing in Patients With Mild Heart Failure. Journal of the American Heart Association, 2019, 8, e010346.	3.7	9
71	Real-world referral pattern and outcomes of diabetic patients who undergo revascularization: data from the prospective Multi-vessel Coronary Artery Disease (MULTICAD) Israeli Registryâ€. European Journal of Cardio-thoracic Surgery, 2019, 56, 328-334.	1.4	3
72	Revascularization Strategies and Survival in Patients With Multivessel Coronary Artery Disease. Annals of Thoracic Surgery, 2019, 107, 106-111.	1.3	10

#	Article	IF	CITATIONS
73	The Association of Body Mass Index and 20-Year All-Cause Mortality Among Patients With Stable Coronary Artery Disease. Heart Lung and Circulation, 2019, 28, 719-726.	0.4	6
74	Characteristics and outcomes associated with 30-day readmissions following acute coronary syndrome 2000–2013: the Acute Coronary Syndrome Israeli Survey. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 738-744.	1.0	5
75	OUP accepted manuscript. Europace, 2019, 21, 1865-1875.	1.7	6
76	Acute myocardial infarction severity, complications, and mortality associated with lack of magnesium intake through consumption of desalinated seawater. Magnesium Research, 2019, 32, 39-50.	0.5	3
77	Comparison of Long-Term Survival Benefits With Cardiac Resynchronization Therapy in Patients With Mild Heart Failure With Versus Without Diabetes Mellitus (from the Multicenter Automatic) Tj ETQq1 1 0.784314 Journal of Cardiology, 2018, 121, 1567-1574.	rgBT /Ove	erlock 10 Tfl
78	Incidence and Prognosis of Pericarditis After ST-Elevation Myocardial Infarction (from the Acute) Tj ETQqO 0 0 rgB <sup>-</sup> 2018, 121, 690-694.	T /Overloc 1.6	k 10 Tf 50 5 15
79	Impact of quadripolar LV leads on heart failure hospitalization rates among patients implanted with CRT-D: data from the Israeli ICD Registry. Journal of Interventional Cardiac Electrophysiology, 2018, 51, 5-12.	1.3	8
80	Low ALT blood levels are associated with lower baseline fitness amongst participants of a cardiac rehabilitation program. Journal of Exercise Science and Fitness, 2018, 16, 1-4.	2.2	15
81	Comparison of patients with multivessel disease treated at centers with and without on-site cardiac surgery. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 865-873.e3.	0.8	14
82	Long-Term Survival With Implantable Cardioverter-Defibrillator in Different Symptomatic Functional Classes of Heart Failure. American Journal of Cardiology, 2018, 121, 615-620.	1.6	10
83	High-grade atrioventricular block in patients with acute myocardial infarction. Insights from a contemporary multi-center survey. Journal of Electrocardiology, 2018, 51, 386-391.	0.9	17
84	Real-life characteristics and outcomes of patients who undergo percutaneous coronary intervention versus coronary artery bypass grafting for left main coronary artery disease: data from the prospective Multi-vessel Coronary Artery Disease (MULTICAD) Israeli Registryâ€. European Journal of Cardio-thoracic Surgery, 2018, 54, 717-723	1.4	12
85	Impact of mobile intensive care unit use on total ischemic time and clinical outcomes in ST-elevation myocardial infarction patients – real-world data from the Acute Coronary Syndrome Israeli Survey. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 497-503.	1.0	5
86	Early Referral to Coronary Artery Bypass Grafting Following Acute Coronary Syndrome, Trends and Outcomes from the Acute Coronary Syndrome Israeli Survey (ACSIS) 2000–2010. Heart Lung and Circulation, 2018, 27, 175-182.	0.4	8
87	De novo mitral regurgitation as a cause of heart failure exacerbation in patients with hypertrophic cardiomyopathy. International Journal of Cardiology, 2018, 252, 122-127.	1.7	3
88	Donorâ€recipient ethnic mismatching impacts short―and longâ€ŧerm results of heart transplantation. Clinical Transplantation, 2018, 32, e13389.	1.6	2
89	Left Ventricular Lead Location and Long-Term Outcomes in Cardiac Resynchronization Therapy Patients. JACC: Clinical Electrophysiology, 2018, 4, 1410-1420.	3.2	20
90	Developing a risk score to predict mortality in the first year after implantable cardioverter defibrillator implantation: Data from the Israeli ICD Registry. Journal of Cardiovascular Electrophysiology, 2018, 29, 1540-1547.	1.7	6

#	Article	IF	CITATIONS
91	Experience with the wearable cardioverter-defibrillator in older patients: Results from the Prospective Registry of Patients Using the Wearable Cardioverter-Defibrillator. Heart Rhythm, 2018, 15, 1379-1386.	0.7	11
92	The role and outcome of cardiac rehabilitation program in patients with atrial fibrillation. Clinical Cardiology, 2018, 41, 1170-1176.	1.8	23
93	Impact of Self-Reported Family History of Premature Cardiovascular Disease on the Outcomes of Patients Hospitalized for Acute Coronary Syndrome (from the Acute Coronary Syndrome Israel Survey) Tj ETQ	q11 <b>0.</b> 7843	314 <b>∉</b> gBT /Ove
94	Oneâ€year followâ€up of the prospective registry of patients using the wearable defibrillator (WEARITâ€II) Tj	ETQq0 0 0 r 1.2	gBT_/Overlock
95	Non-response to Cardiac Resynchronization Therapy. Current Heart Failure Reports, 2018, 15, 315-321.	3.3	17
96	Predictors of longâ€ŧerm mortality with cardiac resynchronization therapy in mild heart failure patients with left bundle branch block. Clinical Cardiology, 2018, 41, 1358-1366.	1.8	4
97	Relation of Atrial Premature Complexes During Exercise Stress Testing to the Risk for the Development of Atrial Fibrillation in Patients Undergoing Cardiac Rehabilitation. American Journal of Cardiology, 2018, 122, 395-399.	1.6	1
98	Participation in an Exercise-Based Cardiac Rehabilitation Program and Functional Improvement of Heart Failure Patients with Preserved Versus Reduced Left Ventricular Systolic Function. Israel Medical Association Journal, 2018, 20, 358-362.	0.1	6
99	Sub-acute vs. Late-onset Presentation of Oncotherapy Related Cardiotoxicity: Predictors of Cardiac Function Recovery and Long-Term Outcome. Israel Medical Association Journal, 2018, 20, 486-490.	0.1	0
100	The Association Between the Risk Scores for Cardiovascular Disease and Long-Term Mortality Following an Acute Coronary Event. Israel Medical Association Journal, 2018, 20, 419-422.	0.1	1
101	Rationale and design of the BUDAPEST-CRT Upgrade Study: a prospective, randomized, multicentre clinical trial. Europace, 2017, 19, euw193.	1.7	17
102	Morbidity and mortality with cardiac resynchronization therapy with pacing vs. with defibrillation in octogenarian patients in a real-world setting. Europace, 2017, 19, euw238.	1.7	11
103	Admission plasma glucose levels within the normal to mildly impaired range and the outcome of patients with acute coronary syndrome. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 738-743.	1.0	5
104	Temporal trends in management and outcomes of patients with acute coronary syndrome according to renal function. International Journal of Cardiology, 2017, 232, 48-52.	1.7	10
105	Gender disparities in the functional significance of anemia among apparently healthy adults. European Journal of Haematology, 2017, 98, 435-442.	2.2	5
106	Temporal trends and outcomes associated with atrial fibrillation observed during acute coronary syndrome: Realâ€world data from the Acute Coronary Syndrome Israeli Survey ( <scp>ACSIS</scp> ), 2000–2013. Clinical Cardiology, 2017, 40, 275-280.	1.8	25
107	Triggers and Timing of Acute Coronary Syndromes. American Journal of Cardiology, 2017, 119, 1560-1565.	1.6	16
108	Sex Differences in the Management and 5-Year Outcome of Young Patients (<55 Years) with Acute Coronary Syndromes. American Journal of Medicine, 2017, 130, 1324.e15-1324.e22.	1.5	39

#	Article	IF	CITATIONS
109	The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study. Cardiovascular Diabetology, 2017, 16, 69.	6.8	23
110	The Effect of Admission Renal Function on the Treatment and Outcome of Patients with Acute Coronary Syndrome. CardioRenal Medicine, 2017, 7, 169-178.	1.9	16
111	Impaired Fasting Glucose Is the Major Determinant of the 20‥ear Mortality Risk Associated With Metabolic Syndrome in Nondiabetic Patients With Stable Coronary Artery Disease. Journal of the American Heart Association, 2017, 6, .	3.7	11
112	Addition of albumin to Traditional Risk Score Improved Prediction of Mortality in Individuals Undergoing Transcatheter Aortic Valve Replacement. Journal of the American Geriatrics Society, 2017, 65, 2413-2417.	2.6	18
113	Risk Stratification for Sudden Cardiac Death in Individuals Without Structural Disease. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	4.8	4
114	Early aspirin initiation following heart transplantation is associated with reduced risk of allograft vasculopathy during longâ€ŧerm followâ€ʉp. Clinical Transplantation, 2017, 31, e13133.	1.6	30
115	Machine learning for prediction of 30-day mortality after ST elevation myocardial infraction: An Acute Coronary Syndrome Israeli Survey data mining study. International Journal of Cardiology, 2017, 246, 7-13.	1.7	77
116	Metformin therapy reduces the risk of malignancy after heart transplantation. Journal of Heart and Lung Transplantation, 2017, 36, 1350-1357.	0.6	14
117	Risk of early, intermediate, and late rejection following heart transplantation: Trends over the past 25Âyears and relation to changes in medical management. Tertiary center experience: The Sheba Heart Transplantation Registry. Clinical Transplantation, 2017, 31, e13063.	1.6	7
118	Outcomes of Patients Presenting With Clinical Indices of Spontaneous Reperfusion in STâ€Elevation Acute Coronary Syndrome Undergoing Deferred Angiography. Journal of the American Heart Association, 2017, 6, .	3.7	11
119	Comparison of Outcomes of Acute Coronary Syndrome in Patients ≥80 Years Versus Those <80 Years in Israel from 2000 to 2013. American Journal of Cardiology, 2017, 120, 1230-1237.	1.6	5
120	Elevated Admission Potassium Levels and 1-Year and 10-Year Mortality Among Patients With Heart Failure. American Journal of the Medical Sciences, 2017, 354, 268-277.	1.1	7
121	Long-Term Survival of Patients With Left Bundle Branch Block Who Are Hypo-Responders to Cardiac Resynchronization Therapy. American Journal of Cardiology, 2017, 120, 825-830.	1.6	11
122	Multicenter Automatic Defibrillator Implantation Trial–Subcutaneous Implantable Cardioverter Defibrillator (MADIT S-ICD): Design and clinical protocol. American Heart Journal, 2017, 189, 158-166.	2.7	31
123	Effect of supplemented intake of omega-3 fatty acids on arrhythmias in patients with ICD: fish oil therapy may reduce ventricular arrhythmia. Journal of Interventional Cardiac Electrophysiology, 2017, 49, 255-261.	1.3	14
124	Effect of cardiac resynchronization therapy on the risk of ventricular tachyarrhythmias in patients with chronic kidney disease. , 2017, 22, e12404.		2
125	Contemporary rates and outcomes of single- vs. dual-coil implantable cardioverter defibrillator lead implantation: data from the Israeli ICD Registry. Europace, 2017, 19, 1485-1492.	1.7	11
126	Cardiac rehabilitation following an acute coronary syndrome: Trends in referral, predictors and mortality outcome in a multicenter national registry between years 2006–2013: Report from the Working Group on Cardiac Rehabilitation, the Israeli Heart Society. European Journal of Preventive Cardiology, 2017, 24, 123-132.	1.8	29

#	Article	IF	CITATIONS
127	Admission blood glucose and 10-year mortality among patients with or without pre-existing diabetes mellitus hospitalized with heart failure. Cardiovascular Diabetology, 2017, 16, 102.	6.8	22
128	Trends in the management and outcomes of patients admitted with acute coronary syndrome complicated by cardiogenic shock over the past decade: Real world data from the acute coronary syndrome Israeli survey (ACSIS). Oncotarget, 2017, 8, 42876-42886.	1.8	8
129	Study of the wearable cardioverter defibrillator in advanced heartâ€failure patients (SWIFT). Journal of Cardiovascular Electrophysiology, 2017, 28, 778-784.	1.7	17
130	The impact of inflammatory rheumatic diseases on the presentation, severity, and outcome of acute coronary syndrome. Clinical Rheumatology, 2016, 35, 233-237.	2.2	10
131	Comparison of acute kidney injury classifications in patients undergoing transcatheter aortic valve implantation: Predictors and longâ€ŧerm outcomes. Catheterization and Cardiovascular Interventions, 2016, 87, 523-531.	1.7	17
132	Relationship between age and inappropriate implantable cardioverter-defibrillator therapy in MADIT-RIT (Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy). Heart Rhythm, 2016, 13, 888-893.	0.7	10
133	Clinical Implications of Complete Left-Sided Reverse Remodeling With CardiacÂResynchronization Therapy. Journal of the American College of Cardiology, 2016, 68, 1268-1276.	2.8	47
134	Gender-Related Cardiovascular Risk in Healthy Middle-Aged Adults. American Journal of Cardiology, 2016, 118, 1669-1673.	1.6	7
135	CHA2DS2-VASc score and clinical outcomes of patients with acute coronary syndrome. European Journal of Internal Medicine, 2016, 36, 57-61.	2.2	38
136	Clinical Aspects of Type 3 Long-QT Syndrome. Circulation, 2016, 134, 872-882.	1.6	162
137	Desalinated seawater supply and all-cause mortality in hospitalized acute myocardial infarction patients from the Acute Coronary Syndrome Israeli Survey 2002–2013. International Journal of Cardiology, 2016, 220, 544-550.	1.7	27
138	Poor Heart Rate Recovery Is Associated With the Development of New-Onset Atrial Fibrillation in Middle-Aged Adults. Mayo Clinic Proceedings, 2016, 91, 1769-1777.	3.0	4
139	Metabolic syndrome is independently associated with increased 20-year mortality in patients with stable coronary artery disease. Cardiovascular Diabetology, 2016, 15, 149.	6.8	42
140	Characteristics and outcomes of diabetic patients with an implantable cardioverter defibrillator in a real world setting: results from the Israeli ICD registry. Cardiovascular Diabetology, 2016, 15, 160.	6.8	5
141	Predictors and Risk of Ventricular Tachyarrhythmias or Death in BlackÂandÂWhite Cardiac Patients. JACC: Clinical Electrophysiology, 2016, 2, 448-455.	3.2	17
142	Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial. Cardiovascular Diabetology, 2016, 15, 11.	6.8	28
143	Sustained clinical benefit of cardiac resynchronization therapy in non-LBBB patients with prolonged PR-interval: MADIT-CRT long-term follow-up. Clinical Research in Cardiology, 2016, 105, 944-952.	3.3	41
144	Short- and Long-Term Prognostic Implications of Jugular Venous Distension in Patients Hospitalized With Acute Heart Failure. American Journal of Cardiology, 2016, 118, 226-231.	1.6	14

#	Article	IF	CITATIONS
145	The wearable cardioverter defibrillator as a bridge to implantable defibrillator post myocardial infarction: what do we know?. Expert Review of Medical Devices, 2016, 13, 627-632.	2.8	0
146	Time Dependence of VentricularÂTachyarrhythmias AfterÂMyocardial Infarction. JACC: Clinical Electrophysiology, 2016, 2, 565-573.	3.2	0
147	Comparison of Noninvasively and Invasively Managed Patients, With or Without Revascularization in Non–ST Elevation Myocardial Infarction (from the Acute Coronary Syndrome Israeli Survey). American Journal of Cardiology, 2016, 118, 1-5.	1.6	8
148	Exercise systolic blood pressure variability is associated with increased risk for new-onset hypertension among normotensive adults. Journal of the American Society of Hypertension, 2016, 10, 527-535.e2.	2.3	7
149	Clinical Outcomes of Single―versus Dualâ€Chamber Implantable Cardioverter Defibrillators: Lessons from the Israeli ICD Registry. Journal of Cardiovascular Electrophysiology, 2016, 27, 718-723.	1.7	6
150	Outcome of contemporary acute coronary syndrome complicated by ventricular tachyarrhythmias. Europace, 2016, 18, 219-226.	1.7	27
151	Temporal trends in the outcomes of patients with acute myocardial infarction associated with renal dysfunction over the past decade. European Journal of Internal Medicine, 2016, 29, 88-92.	2.2	10
152	Relative Wall Thickness and the Risk for Ventricular Tachyarrhythmias in Patients With Left Ventricular Dysfunction. Journal of the American College of Cardiology, 2016, 67, 303-312.	2.8	46
153	Association between statin treatment and LDL-cholesterol levels on the rate of ST-elevation myocardial infarction among patients with acute coronary syndromes: ACS Israeli Survey (ACSIS) 2002–2010. International Journal of Cardiology, 2016, 210, 133-138.	1.7	6
154	Relation of QRS Duration to Clinical Benefit of Cardiac Resynchronization Therapy in Mild Heart Failure Patients Without Left Bundle Branch Block. Circulation: Heart Failure, 2016, 9, e002667.	3.9	15
155	Use of exercise capacity to improve SCORE risk prediction model in asymptomatic adults. European Heart Journal, 2016, 37, 2300-2306.	2.2	26
156	Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 100-108.	2.2	138
157	Body mass index and the risk of new-onset atrial fibrillation in middle-aged adults. American Heart Journal, 2016, 173, 41-48.	2.7	50
158	Brain natriuretic peptide and the risk of ventricular tachyarrhythmias in mildly symptomatic heart failure patients enrolled in MADIT-CRT. Heart Rhythm, 2016, 13, 852-859.	0.7	11
159	Obesity and exercise-induced ectopic ventricular arrhythmias in apparently healthy middle aged adults. European Journal of Preventive Cardiology, 2016, 23, 511-517.	1.8	21
160	Prevalence and Significance of Unrecognized Renal Dysfunction in Patients with Acute Coronary Syndrome. American Journal of Medicine, 2016, 129, 187-194.	1.5	15
161	Cardiac Resynchronization in Different Age Groups: A MADIT-CRT Long-Term Follow-Up Substudy. Journal of Cardiac Failure, 2016, 22, 143-149.	1.7	9
162	Lessons learned from the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Trends in Cardiovascular Medicine, 2016, 26, 137-146.	4.9	7

#	Article	IF	CITATIONS
163	Incidence and Clinical Features of Early Stent Thrombosis in the Era of New P2y12 Inhibitors (PLATIS-2). PLoS ONE, 2016, 11, e0157437.	2.5	5
164	Early intervention and longâ€ŧerm outcome with cardiac resynchronization therapy in patients without a history of advanced heart failure symptoms. European Journal of Heart Failure, 2015, 17, 964-970.	7.1	11
165	Reduced risk of lifeâ€threatening ventricular tachyarrhythmias with cardiac resynchronization therapy: relationship to left ventricular ejection fraction. European Journal of Heart Failure, 2015, 17, 971-978.	7.1	23
166	Clinical impact of diabetes mellitus in patients undergoing transcatheter aortic valve replacement. Cardiovascular Diabetology, 2015, 14, 131.	6.8	23
167	Identification of Lowâ€Risk Adult Congenital LQTS Patients. Journal of Cardiovascular Electrophysiology, 2015, 26, 853-858.	1.7	7
168	Clinical Outcomes in Patients with Severe Renal Dysfunction Including Dialysis Following Defibrillator Implantation. American Journal of Nephrology, 2015, 42, 295-304.	3.1	9
169	Time-dependent risk reduction of ventricular tachyarrhythmias in cardiac resynchronization therapy patients: a MADIT-RIT sub-study. Europace, 2015, 17, 1085.1-1091.	1.7	16
170	Time-dependent relation between smoking cessation and improved exercise tolerance in apparently healthy middle-age men and women. European Journal of Preventive Cardiology, 2015, 22, 807-814.	1.8	9
171	The association between admission systolic blood pressure of heart failure patients with preserved systolic function and mortality outcomes. European Journal of Internal Medicine, 2015, 26, 807-812.	2.2	20
172	The association between elevated admission systolic blood pressure in patients with acute coronary syndrome and favorable early and late outcomes. Journal of the American Society of Hypertension, 2015, 9, 97-103.	2.3	14
173	Effects of Statins on First and Recurrent Supraventricular Arrhythmias in Patients With Mild Heart Failure (from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac) Tj ETQq1 1 0.784314 rgBT	/O <b>ve</b> rlock	1 <b>@</b> Tf 50 3 <sup>37</sup>
174	Coronary CT angiography for the detection of coronary artery stenosis in patients referred forÂtranscatheter aortic valve replacement. Journal of Cardiovascular Computed Tomography, 2015, 9, 31-41.	1.3	49
175	Hereditary Arrhythmias. In Clinical Practice, 2015, , 167-190.	0.0	0
176	Efficacy of exercise training in symptomatic patients with hypertrophic cardiomyopathy: Results of a structured exercise training program in a cardiac rehabilitation center. European Journal of Preventive Cardiology, 2015, 22, 13-19.	1.8	74
177	Cryotherapy ablation of parahisian accessory pathways in children. Heart Rhythm, 2015, 12, 917-925.	0.7	20
178	Outcome of Patients with Advanced Heart Failure Who Receive Deviceâ€Based Therapy for Primary Prevention of Sudden Cardiac Death: Insights from the Israeli ICD Registry. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 738-745.	1.2	4
179	Long-Term Outcomes With Cardiac Resynchronization Therapy in Patients With Mild Heart Failure With Moderate Renal Dysfunction. Circulation: Heart Failure, 2015, 8, 725-732.	3.9	18
180	Temporal trends in management and outcome of diabetic and non-diabetic patients with acute coronary syndrome (ACS): Residual risk of long-term mortality persists. International Journal of Cardiology, 2015, 179, 546-551.	1.7	21

#	Article	IF	CITATIONS
181	The association between cardiorespiratory fitness and cardiovascular risk may be modulated by known cardiovascular risk factors. American Heart Journal, 2015, 169, 916-923.e1.	2.7	25
182	Changes in Drug Utilization and Outcome With Cardiac Resynchronization Therapy: A MADIT-CRT Substudy. Journal of Cardiac Failure, 2015, 21, 541-547.	1.7	8
183	Exercise Blood Pressure and the Risk for Future Hypertension Among Normotensive Middleâ€Aged Adults. Journal of the American Heart Association, 2015, 4, .	3.7	43
184	Ethnic Differences Among Implantable Cardioverter Defibrillators Recipients in Israel. American Journal of Cardiology, 2015, 115, 1102-1106.	1.6	4
185	Recent Temporal Trends in the Presentation, Management, and Outcome of Women Hospitalized with Acute Coronary Syndromes. American Journal of Medicine, 2015, 128, 380-388.	1.5	21
186	Comparison of the Usefulness of Heart Rate Variability Versus Exercise Stress Testing for the Detection of Myocardial Ischemia in Patients Without Known Coronary Artery Disease. American Journal of Cardiology, 2015, 115, 1518-1522.	1.6	18
187	Sex Differences in Longâ€Term Outcomes With Cardiac Resynchronization Therapy in Mild Heart Failure Patients With Left Bundle Branch Block. Journal of the American Heart Association, 2015, 4, .	3.7	37
188	Impaired fasting glucose and left ventricular diastolic dysfunction in middle-age adults: a retrospective cross-sectional analysis of 2971 subjects. Cardiovascular Diabetology, 2015, 14, 119.	6.8	22
189	Contemporary rates of appropriate shock therapy in patients who receive implantable device therapy in a real-world setting: From the Israeli ICD Registry. Heart Rhythm, 2015, 12, 2426-2433.	0.7	82
190	Inverse Relationship of Blood Pressure to Long-Term Outcomes and Benefit of Cardiac Resynchronization Therapy in Patients With Mild Heart Failure. Circulation: Heart Failure, 2015, 8, 921-926.	3.9	10
191	Inverse Relationship Between MembranousÂSeptal Length and the RiskÂofÂAtrioventricular Block in PatientsÂUndergoing Transcatheter AorticÂValve Implantation. JACC: Cardiovascular Interventions, 2015, 8, 1218-1228.	2.9	170
192	Short and long term survival following hospitalization with a primary versus non-primary diagnosis of acute heart failure. European Journal of Internal Medicine, 2015, 26, 420-424.	2.2	6
193	Use of the Wearable Cardioverter Defibrillator in High-Risk Cardiac Patients. Circulation, 2015, 132, 1613-1619.	1.6	199
194	The significance of pulmonary arterial hypertension pre- and post-transfemoral aortic valve implantation for severe aortic stenosis. Journal of Cardiology, 2015, 65, 337-342.	1.9	20
195	Response to Letter Regarding, "PR Interval Identifies Clinical Response in Patients With Non-Left Bundle Branch Block: A Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy Sub-Study―by Kutyifa et al. Circulation: Arrhythmia and Electrophysiology, 2014 7 1280-1280	4.8	3
196	Predictors and Outcome of Sustained Improvement in Left Ventricular Function in Dilated Cardiomyopathy. Clinical Cardiology, 2014, 37, 687-692.	1.8	9
197	Left Ventricular Pacing Threshold and Outcome in MADIT RT. Journal of Cardiovascular Electrophysiology, 2014, 25, 1005-1011.	1.7	7
198	Influenza vaccine and survival in acute heart failure. European Journal of Heart Failure, 2014, 16, 264-270.	7.1	39

#	Article	IF	CITATIONS
199	Multidisciplinary rehabilitation program in recently hospitalized patients with heart failure and preserved ejection fraction: Rationale and design of a randomized controlled trial. American Heart Journal, 2014, 168, 830-837.e1.	2.7	12
200	Comparison of Age (<75ÂYears Versus ≥75ÂYears) to Risk of Ventricular Tachyarrhythmias and Implantable Cardioverter Defibrillator Shocks (from the Multicenter Automatic Defibrillator) Tj ETQq0 0 0 rgBT /O	verlock 10 1.6	Tf 50 702 T 14
	114, 1855-1860.		
201	Renal Dysfunction and Clinical Outcomes of Patients Undergoing ICD and CRTD Implantation: Data from the Israeli ICD Registry. Journal of Cardiovascular Electrophysiology, 2014, 25, 990-997.	1.7	13
202	Predictors of Spontaneous Reverse Remodeling in Mild Heart Failure Patients With Left Ventricular Dysfunction. Circulation: Heart Failure, 2014, 7, 565-572.	3.9	24
203	Functional Response to Cardiac Resynchronization Therapy in Patients with Renal Dysfunction and Subsequent Longâ€Term Mortality. Journal of Cardiovascular Electrophysiology, 2014, 25, 1188-1195.	1.7	13
204	Role of defibrillation threshold testing during implantable cardioverter-defibrillator placement: Data from the Israeli ICD Registry. Heart Rhythm, 2014, 11, 814-821.	0.7	13
205	Aspiration Thrombectomy in Patients With ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (from the Acute Coronary Syndrome Israeli Survey 2010). American Journal of Cardiology, 2014, 113, 809-814.	1.6	4
206	Comparison of Statin Alone Versus Bezafibrate and Statin Combination in Patients With Diabetes Mellitus and Acute Coronary Syndrome. American Journal of Cardiology, 2014, 113, 12-16.	1.6	12
207	Clinical characteristics and outcomes of elderly patients treated with an implantable cardioverter-defibrillator or cardiac resynchronization therapy in a real-world setting: Data from the Israeli ICD Registry. Heart Rhythm, 2014, 11, 435-441.	0.7	28
208	Time dependent changes in high density lipoprotein cholesterol and cardiovascular risk. International Journal of Cardiology, 2014, 173, 295-299.	1.7	10
209	A Metric for Evaluating the Cardiac Response to ResynchronizationÂTherapy. American Journal of Cardiology, 2014, 113, 1371-1377.	1.6	11
210	The Effect of Intermittent Atrial Tachyarrhythmia on Heart Failure or Death inÂCardiac Resynchronization Therapy WithÂDefibrillator Versus Implantable Cardioverter-Defibrillator Patients. Journal of the American College of Cardiology, 2014, 63, 1190-1197.	2.8	28
211	Survival after intervention in patients with low gradient severe aortic stenosis and preserved left ventricular function. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, 2823-2828.	0.8	12
212	Survival with Cardiac-Resynchronization Therapy in Mild Heart Failure. New England Journal of Medicine, 2014, 370, 1694-1701.	27.0	283
213	Temporal trends in all-cause mortality of smokers versus non-smokers hospitalized with ST-segment elevation myocardial infarction. International Journal of Cardiology, 2014, 176, 171-176.	1.7	24
214	Congenital Long QT Syndromes: Prevalence, Pathophysiology and Management. Paediatric Drugs, 2014, 16, 447-456.	3.1	28
215	Temporal trends in management of hypertension among Israeli adults, 2002–2010: Lesson from the Acute Coronary Syndromes Israeli Survey (ACSIS). Journal of the American Society of Hypertension, 2014, 8, 94-102.	2.3	5
216	Factors Affecting Survival in Men Versus Women Following Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2014, 113, 701-705.	1.6	31

#	Article	IF	CITATIONS
217	Syncope in Genotype-Negative Long QT Syndrome Family Members. American Journal of Cardiology, 2014, 114, 1223-1228.	1.6	6
218	Comparison of Low Versus High (>40Âmm Hg) Pulse Pressure to Predict the Benefit of Cardiac Resynchronization Therapy for Heart Failure (from the Multicenter Automatic Defibrillator) Tj ETQq0 0 0 rgBT /C	)verlock 1(	0 Tf 50 702 Td
219	1053-1058. Cardiac resynchronization therapy is associated with reductions in left atrial volume and inappropriate implantable cardioverter-defibrillator therapy in MADIT-CRT. Heart Rhythm, 2014, 11, 1001-1007.	0.7	4
220	Smoking is associated with an increased risk of first and recurrent ventricular tachyarrhythmias in ischemic and nonischemic patients with mild heart failure: A MADIT-CRT substudy. Heart Rhythm, 2014, 11, 822-827.	0.7	8
221	The Israel Nationwide Heart Failure Survey: Sex Differences in Early and Late Mortality for Hospitalized Heart Failure Patients. Journal of Cardiac Failure, 2014, 20, 193-198.	1.7	13
222	PR Interval Identifies Clinical Response in Patients With Non–Left Bundle Branch Block. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 645-651.	4.8	98
223	Relation Between Stroke Volume Index to Risk of Death in Patients With Low-Gradient Severe Aortic Stenosis and Preserved Left Ventricular Function. American Journal of Cardiology, 2014, 114, 449-455.	1.6	15
224	Abstract 13444: Complete Left-Sided Reverse Remodeling in Cardiac Resynchronization Therapy and Clinical Implications: a MADIT-CRT Long-term Follow-up Sub-study. Circulation, 2014, 130, .	1.6	0
225	The Influence of Left Ventricular Ejection Fraction on the Effectiveness of Cardiac Resynchronization Therapy. Journal of the American College of Cardiology, 2013, 61, 936-944.	2.8	86
226	Dyssynchrony and the Risk of Ventricular Arrhythmias. JACC: Cardiovascular Imaging, 2013, 6, 432-444.	5.3	72
227	Instability of ventricular repolarization in long QT syndrome: Is the corrected QT interval sufficient for risk assessment?. Heart Rhythm, 2013, 10, 1176-1177.	0.7	Ο
228	Risk of life-threatening cardiac events among patients with long QT syndrome and multiple mutations. Heart Rhythm, 2013, 10, 378-382.	0.7	46
229	Prognostic implications of mutation-specific QTc standard deviation in congenital long QT syndrome. Heart Rhythm, 2013, 10, 720-725.	0.7	20
230	Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator. European Heart Journal, 2013, 34, 2230-2242.	2.2	104
231	Genotype pecific Risk Stratification and Management of Patients with Long QT Syndrome. Annals of Noninvasive Electrocardiology, 2013, 18, 499-509.	1.1	37
232	Left ventricular lead location and the risk of ventricular arrhythmias in the MADIT-CRT trial. European Heart Journal, 2013, 34, 184-190.	2.2	42
233	Response to Letter Regarding Article, "Predictors of Response to Cardiac Resynchronization Therapy in The Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT)†Circulation, 2012, 125, .	1.6	0
234	Lipid-Modifying Therapies and Risk of Pancreatitis. JAMA - Journal of the American Medical Association, 2012, 308, 804.	7.4	140

#	Article	IF	CITATIONS
235	Mutations in Cytoplasmic Loops of the KCNQ1 Channel and the Risk of Life-Threatening Events. Circulation, 2012, 125, 1988-1996.	1.6	187
236	Predictors of Super-Response to Cardiac Resynchronization Therapy and Associated Improvement in Clinical Outcome. Journal of the American College of Cardiology, 2012, 59, 2366-2373.	2.8	252
237	Evaluation of a Patient with a Positive Family History for Long QT Syndrome. Cardiac Electrophysiology Clinics, 2012, 4, 239-248.	1.7	1
238	Combined assessment of sex- and mutation-specific information for risk stratification in type 1 long QT syndrome. Heart Rhythm, 2012, 9, 892-898.	0.7	58
239	In Silico Cardiac Risk Assessment in Patients With Long QT Syndrome. Journal of the American College of Cardiology, 2012, 60, 2182-2191.	2.8	33
240	Trigger-specific ion-channel mechanisms, risk factors, and response to therapy in type 1 long QT syndrome. Heart Rhythm, 2012, 9, 49-56.	0.7	51
241	Applicability of a Risk Score for Prediction of the Long-Term (8-Year) Benefit of the Implantable Cardioverter-Defibrillator. Journal of the American College of Cardiology, 2012, 59, 2075-2079.	2.8	137
242	Reduction in Life-Threatening Ventricular Tachyarrhythmias in Statin-Treated Patients With Nonischemic Cardiomyopathy Enrolled in the MADIT-CRT (Multicenter Automatic Defibrillator) Tj ETQq0 0 0 rgBT	/Qverlock 2.8	109Tf 50 462
243	Effect of Cardiac Resynchronization Therapy on the Risk of First and Recurrent Ventricular Tachyarrhythmic Events in MADIT-CRT. Journal of the American College of Cardiology, 2012, 60, 1809-1816.	2.8	65
244	Risk of Mortality for Ventricular Arrhythmia in Ambulatory LVAD Patients. Journal of Cardiovascular Electrophysiology, 2012, 23, 515-520.	1.7	84
245	The Role of the Implantable Cardioverter-Defibrillator in the Long QT Syndrome. Cardiac Electrophysiology Clinics, 2012, 4, 87-95.	1.7	2
246	Mutation and gender-specific risk in type 2 long QT syndrome: Implications for risk stratification for life-threatening cardiac events in patients with long QT syndrome. Heart Rhythm, 2011, 8, 1537-1543.	0.7	117
247	Cardiac Resynchronization Therapy Is More Effective in Women Than in Men. Journal of the American College of Cardiology, 2011, 57, 813-820.	2.8	291
248	Risk for Life-Threatening Cardiac Events in Patients With Genotype-Confirmed Long-QT Syndrome and Normal-Range Corrected QT Intervals. Journal of the American College of Cardiology, 2011, 57, 51-59.	2.8	268
249	Risk Factors for Recurrent Syncope and Subsequent Fatal or Near-Fatal Events in Children and Adolescents With Long QT Syndrome. Journal of the American College of Cardiology, 2011, 57, 941-950.	2.8	110
250	Reverse Remodeling and the Risk of Ventricular Tachyarrhythmias in the MADIT-CRT (Multicenter) Tj ETQq0 0 0 rg American College of Cardiology, 2011, 57, 2416-2423.	gBT /Overl 2.8	ock 10 Tf 50 200
251	Reduction of the Risk of Recurring Heart Failure Events With Cardiac Resynchronization Therapy. Journal of the American College of Cardiology, 2011, 58, 729-737.	2.8	66
252	Left Atrial Contractile Function Following a Successful Modified Maze Procedure at Surgery and the Risk for Subsequent Thromboembolic Stroke. Journal of the American College of Cardiology, 2011, 58, 1614-1621.	2.8	76

#	ARTICLE	IF	CITATIONS
253	Cardiac Resynchronization Therapy Reduces Left Atrial Volume and the Risk of Atrial Tachyarrhythmias in MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac) Tj ETQq1 1	0.22884314	rg®J /Overlo
254	Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial–Cardiac Resynchronization Therapy (MADIT-CRT). Circulation, 2011, 123, 1061-1072.	1.6	714
255	Predictors of Response to Cardiac Resynchronization Therapy in the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT). Circulation, 2011, 124, 1527-1536.	1.6	275
256	Long-term implications of cumulative right ventricular pacing among patients with an implantable cardioverter-defibrillator. Heart Rhythm, 2011, 8, 212-218.	0.7	78
257	Thrombospondin-4 polymorphism (A387P) predicts cardiovascular risk in postinfarction patients with high HDL cholesterol and C-reactive protein levels. Thrombosis and Haemostasis, 2011, 106, 1170-1178.	3.4	21
258	Age and Effectiveness of Prophylactic Implantable Cardioverter-Defibrillators. Annals of Internal Medicine, 2011, 154, 505.	3.9	2
259	Improved Outcome with Preventive Cardiac Resynchronization Therapy in the Elderly: A MADITâ€CRT Substudy. Journal of Cardiovascular Electrophysiology, 2011, 22, 892-897.	1.7	53
260	Effect of Elapsed Time From Coronary Revascularization to Implantation of a Cardioverter Defibrillator on Long-Term Survival in the MADIT-II Trial. Journal of Cardiovascular Electrophysiology, 2011, 22, 1237-1242.	1.7	22
261	Relation of Bundle Branch Block to Long-Term (Four-Year) Mortality in Hospitalized Patients With Systolic Heart Failure. American Journal of Cardiology, 2011, 107, 540-544.	1.6	54
262	Predictors and Course of High-Degree Atrioventricular Block After Transcatheter Aortic Valve Implantation Using the CoreValve Revalving system. American Journal of Cardiology, 2011, 108, 1600-1605.	1.6	115
263	Wearable Defibrillator in Congenital Structural Heart Disease and Inherited Arrhythmias. American Journal of Cardiology, 2011, 108, 1632-1638.	1.6	36
264	Genetics of Sudden Cardiac Death. Current Cardiology Reports, 2011, 13, 364-376.	2.9	27
265	Risk of Syncope in Family Members Who Are Genotype-Negative for a Family-Associated Long-QT Syndrome Mutation. Circulation: Cardiovascular Genetics, 2011, 4, 491-499.	5.1	9
266	Relationship between improvement in left ventricular dyssynchrony and contractile function and clinical outcome with cardiac resynchronization therapy: the MADIT-CRT trial. European Heart Journal, 2011, 32, 1720-1729.	2.2	107
267	Risk of Recurrent Cardiac Events After Onset of Menopause in Women With Congenital Long-QT Syndrome Types 1 and 2. Circulation, 2011, 123, 2784-2791.	1.6	69
268	Dyssynchrony, Contractile Function, and Response to Cardiac Resynchronization Therapy. Circulation: Heart Failure, 2011, 4, 433-440.	3.9	71
269	Left Ventricular Lead Position and Clinical Outcome in the Multicenter Automatic Defibrillator Implantation Trial–Cardiac Resynchronization Therapy (MADIT-CRT) Trial. Circulation, 2011, 123, 1159-1166.	1.6	510
270	Use of Mutant-Specific Ion Channel Characteristics for Risk Stratification of Long QT Syndrome Patients. Science Translational Medicine, 2011, 3, 76ra28.	12.4	45

#	Article	IF	CITATIONS
271	Timing of Coronary Angiography and Outcome in Patients with Non-ST Elevation Acute Coronary Syndromes and Kidney Disease: Real-World Data from the Acute Coronary Syndromes Israeli Survey. Cardiology, 2011, 119, 224-234.	1.4	9
272	Clinical course and outcome of patients enrolled in US and non-US centres in MADIT-CRT. European Heart Journal, 2011, 32, 2697-2704.	2.2	10
273	Response to preventive cardiac resynchronization therapy in patients with ischaemic and nonischaemic cardiomyopathy in MADIT-CRT. European Heart Journal, 2011, 32, 1622-1630.	2.2	128
274	Implantable cardioverter defibrillators in patients with coronary artery disease. , 2011, , 417-427.		0
275	Influence of Diabetes Mellitus on Outcome in Patients Over 40 Years of Age With the Long QT Syndrome. American Journal of Cardiology, 2010, 105, 87-89.	1.6	3
276	Mutation-Specific Risk in Two Genetic Forms of Type 3 Long QT Syndrome. American Journal of Cardiology, 2010, 105, 210-213.	1.6	28
277	Relation of Body Mass Index to Sudden Cardiac Death and the Benefit of Implantable Cardioverter–Defibrillator in Patients With Left Ventricular Dysfunction After Healing of Myocardial Infarction. American Journal of Cardiology, 2010, 105, 581-586.	1.6	35
278	Betaâ€Blocker Efficacy in Highâ€Risk Patients with the Congenital Longâ€QT Syndrome Types 1 and 2: Implications for Patient Management. Journal of Cardiovascular Electrophysiology, 2010, 21, 893-901.	1.7	99
279	Risk Factors for Recurrent Heart Failure Events in the Multicenter Automatic Defibrillator Implantation Trial II (MADITâ€II). Journal of Cardiovascular Electrophysiology, 2010, 21, 1217-1223.	1.7	9
280	Ion Channel Mechanisms Related to Sudden Cardiac Death in Phenotype-Negative Long-QT Syndrome Genotype-Phenotype Correlations of the KCNQ1(S349W) Mutation. Journal of Cardiovascular Electrophysiology, 2010, 22, no-no.	1.7	6
281	Long QT Syndrome in Africanâ€Americans. Annals of Noninvasive Electrocardiology, 2010, 15, 73-76.	1.1	16
282	Family with Suspect LQTS. , 2010, 15, 384-386.		1
283	Relation Between Renal Function and Outcomes in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome. Archives of Internal Medicine, 2010, 170, 888.	3.8	66
284	Predictors of longâ€ŧerm (4â€year) mortality in elderly and young patients with acute heart failure. European Journal of Heart Failure, 2010, 12, 833-840.	7.1	57
285	Long-Term Benefit of Primary Prevention With an Implantable Cardioverter-Defibrillator. Circulation, 2010, 122, 1265-1271.	1.6	205
286	Time dependence of life-threatening ventricular tachyarrhythmias after coronary revascularization in MADIT-CRT. Heart Rhythm, 2010, 7, 1421-1427.	0.7	25
287	Relation between renal function and response to cardiac resynchronization therapy in Multicenter Automatic Defibrillator Implantation Trial—Cardiac Resynchronization Therapy (MADIT-CRT). Heart Rhythm, 2010, 7, 1777-1782.	0.7	41
288	Risk of Fatal Arrhythmic Events in Long QT Syndrome Patients After Syncope. Journal of the American College of Cardiology, 2010, 55, 783-788.	2.8	123

#	Article	IF	CITATIONS
289	Trigger-specific risk factors and response to therapy in long QT syndrome type 2. Heart Rhythm, 2010, 7, 1797-1805.	0.7	75
290	Long-term Benefit of High-Density Lipoprotein Cholesterol–Raising Therapy With Bezafibrate. Archives of Internal Medicine, 2009, 169, 508.	3.8	41
291	Reversible Acute Kidney Injury following Contrast Exposure and the Risk of Long-Term Mortality. American Journal of Nephrology, 2009, 29, 136-144.	3.1	85
292	Relation of Clinical Benefit of Raising High-Density Lipoprotein Cholesterol to Serum Levels of Low-Density Lipoprotein Cholesterol in Patients With Coronary Heart Disease (from the Bezafibrate) Tj ETQq0 0	0 r <b>gB</b> T /Ov	verłazck 10 Tf :
293	Efficacy of Medical Therapy for the Reduction of Heart Failure Events in Patients with Implanted Cardioverter Defibrillators. Journal of Cardiovascular Electrophysiology, 2009, 20, 395-400.	1.7	9
294	Clinical Implications for Patients With Long QT Syndrome Who Experience a Cardiac Event During Infancy. Journal of the American College of Cardiology, 2009, 54, 832-837.	2.8	82
295	Genotype-Phenotype Aspects of Type 2 Long QT Syndrome. Journal of the American College of Cardiology, 2009, 54, 2052-2062.	2.8	236
296	Predictors of long-term mortality in Multicenter Automatic Defibrillator Implantation Trial II (MADIT) Tj ETQq0 0	0 rgBT ∕Ov	erlock 10 Tf 5
297	Implantable Cardioverter Defibrillator in Patients with Coronary Artery Disease. Cardiac Electrophysiology Clinics, 2009, 1, 79-93.	1.7	0
298	Implantable Cardioverter Defibrillator Efficacy and Chronic Kidney Disease: Competing Risks of Arrhythmic and Nonarrhythmic Mortality. Journal of Cardiovascular Electrophysiology, 2008, 19, 1281-1283.	1.7	17
299	Phenotypic Variability in Caucasian and Japanese Patients with Matched LQT1 Mutations. Annals of Noninvasive Electrocardiology, 2008, 13, 234-241.	1.1	11
300	Cumulative Burden of Atherosclerotic Risk Genotypes and the Age at Onset of a First Myocardial Infarction: A Caseâ€Only Carriership Approach. Annals of Noninvasive Electrocardiology, 2008, 13, 287-294.	1.1	3
301	Long QT Syndrome. Current Problems in Cardiology, 2008, 33, 629-694.	2.4	174
302	Implantable Device Therapy. Progress in Cardiovascular Diseases, 2008, 50, 449-474.	3.1	21
303	Risk Stratification for Primary Implantation of a Cardioverter-Defibrillator in Patients With Ischemic Left Ventricular Dysfunction. Journal of the American College of Cardiology, 2008, 51, 288-296.	2.8	492
304	Secondary Prevention With Bezafibrate Therapy for the Treatment of Dyslipidemia. Journal of the American College of Cardiology, 2008, 51, 459-465.	2.8	36
305	Long QT Syndrome. Journal of the American College of Cardiology, 2008, 51, 2291-2300.	2.8	458
306	Long-QT Syndrome After Age 40. Circulation, 2008, 117, 2192-2201.	1.6	134

#	Article	IF	CITATIONS
307	Risk Factors for Aborted Cardiac Arrest and Sudden Cardiac Death in Children With the Congenital Long-QT Syndrome. Circulation, 2008, 117, 2184-2191.	1.6	255
308	Importance of Knowing the Genotype and the Specific Mutation When Managing Patients With Long-QT Syndrome. Circulation: Arrhythmia and Electrophysiology, 2008, 1, 219-226.	4.8	30
309	Update on the use of fibrates: focus on bezafibrate. Vascular Health and Risk Management, 2008, 4, 131-141.	2.3	62
310	Risk Factors for Sudden Cardiac Death in Patients with Chronic Renal Insufficiency and Left Ventricular Dysfunction. American Journal of Nephrology, 2007, 27, 7-14.	3.1	26
311	Clinical Aspects of Type-1 Long-QT Syndrome by Location, Coding Type, and Biophysical Function of Mutations Involving the KCNQ1 Gene. Circulation, 2007, 115, 2481-2489.	1.6	394
312	Treatment of Arrhythmias and Use of Implantable Cardioverter-Defibrillators to Improve Survival in Elderly Patients with Cardiac Disease. Clinics in Geriatric Medicine, 2007, 23, 205-219.	2.6	18
313	Treatment of Arrhythmias and Use of Implantable Cardioverter-Defibrillators to Improve Survival in Elderly Patients with Cardiac Disease. Heart Failure Clinics, 2007, 3, 519-528.	2.1	7
314	Long QT Syndrome in Adults. Journal of the American College of Cardiology, 2007, 49, 329-337.	2.8	369
315	Long QT Syndrome and Pregnancy. Journal of the American College of Cardiology, 2007, 49, 1092-1098.	2.8	299
316	Inverse Relationship of Blood Pressure Levels to Sudden Cardiac Mortality and Benefit of the Implantable Cardioverter-Defibrillator in Patients With Ischemic Left Ventricular Dysfunction. Journal of the American College of Cardiology, 2007, 49, 1427-1433.	2.8	29
317	Obesity As a Risk Factor for Sustained Ventricular Tachyarrhythmias in MADIT II Patients. Journal of Cardiovascular Electrophysiology, 2007, 18, 181-184.	1.7	88
318	Polymorphism in the Cholesteryl Ester Transfer Protein Gene and the Risk of Early Onset Myocardial Infarction among Cigarette Smokers. Annals of Noninvasive Electrocardiology, 2007, 12, 364-374.	1.1	12
319	Prognostic Significance of Fragmented QRS Complex for Predicting the Risk of Recurrent Cardiac Events in Patients With Q-Wave Myocardial Infarction. American Journal of Cardiology, 2007, 100, 583-586.	1.6	118
320	Time Dependence of Defibrillator Benefit After Coronary Revascularization in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. Journal of the American College of Cardiology, 2006, 47, 1811-1817.	2.8	96
321	Corrected QT Variability in Serial Electrocardiograms in Long QT Syndrome. Journal of the American College of Cardiology, 2006, 48, 1047-1052.	2.8	98
322	QT Interval: How to Measure It and What Is "Normal". Journal of Cardiovascular Electrophysiology, 2006, 17, 333-336.	1.7	447
323	Cigarette Smoking and the Risk of Supraventricular and Ventricular Tachyarrhythmias in High-Risk Cardiac Patients with Implantable Cardioverter Defibrillators. Journal of Cardiovascular Electrophysiology, 2006, 17, 931-936.	1.7	69
324	Clinical Course and Risk Stratification of Patients Affected with the Jervell and Langeâ€Nielsen Syndrome. Journal of Cardiovascular Electrophysiology, 2006, 17, 1161-1168.	1.7	78

#	Article	IF	CITATIONS
325	Relation Between On-Treatment Increments in Serum High-Density Lipoprotein Cholesterol Levels and Cardiac Mortality in Patients With Coronary Heart Disease (from the Bezafibrate Infarction) Tj ETQq1 1 C	).784314 r <b>g</b> ВТ	/Overkesck 10 Tf
326	Relations Among Renal Function, Risk of Sudden Cardiac Death, and Benefit of the Implanted Cardiac Defibrillator in Patients With Ischemic Left Ventricular Dysfunction. American Journal of Cardiology, 2006, 98, 485-490.	1.6	195
327	Effectiveness of the Implantable Cardioverter Defibrillator in Blacks Versus Whites (from MADIT-II). American Journal of Cardiology, 2006, 98, 1383-1386.	1.6	34
328	Risk of Aborted Cardiac Arrest or Sudden Cardiac Death During Adolescence in the Long-QT Syndrome. JAMA - Journal of the American Medical Association, 2006, 296, 1249.	7.4	258
329	Causes and Consequences of Heart Failure After Prophylactic Implantation of a Defibrillator in the Multicenter Automatic Defibrillator Implantation Trial II. Circulation, 2006, 113, 2810-2817.	1.6	213
330	Polymorphism in the Angiotensinogen Gene, Hypertension, and Ethnic Differences in the Risk of Recurrent Coronary Events. Hypertension, 2006, 48, 693-699.	2.7	23
331	Cost-Effectiveness of Implanted Defibrillators in Young People with Inherited Cardiac Arrhythmias. Annals of Noninvasive Electrocardiology, 2005, 10, 67-83.	1.1	32
332	Sudden cardiac death without structural heart disease: Update on the long QT and brugada syndromes. Current Cardiology Reports, 2005, 7, 349-356.	2.9	20
333	Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. Cmaj, 2005, 172, 1461-1471.	2.0	305
334	Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography A randomized controlled trial and review of the current literature. European Heart Journal, 2004, 25, 212-218.	2.2	138
335	Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial Infarction. Circulation, 2004, 109, 3171-3175.	1.6	1,274
336	Peroxisome Proliferator–Activated Receptor Ligand Bezafibrate for Prevention of Type 2 Diabetes Mellitus in Patients With Coronary Artery Disease. Circulation, 2004, 109, 2197-2202.	1.6	157
337	Adenosine protects against angiotensin II-induced apoptosis in rat cardiocyte cultures. Molecular and Cellular Biochemistry, 2003, 252, 133-139.	3.1	20
338	Primary angioplasty with routine stenting compared with thrombolytic therapy in elderly patients with acute myocardial infarction. American Heart Journal, 2003, 145, 862-867.	2.7	54
339	Current Smoking, Smoking Cessation, and the Risk of Sudden Cardiac Death in Patients With Coronary Artery Disease. Archives of Internal Medicine, 2003, 163, 2301.	3.8	141
340	Time-Dependent Gender Differences in the Clinical Course of Patients with the Congenital Long-QT Syndrome. , 0, , 28-36.		2
341	Pharmacists as members of an interdisciplinary pulmonary embolism response team. JACCP Journal of the American College of Clinical Pharmacy, 0, , .	1.0	3